非侵襲的出生前検査の世界市場分析:妊娠期間別(0-12週、13-24週、25-36週)、妊娠リスクレベル別、(高リスク – 平均リスク、低リスク)、地域別(アメリカ、イギリス、ドイツ、日本、中国、ブラジル)、セグメント予測、2014-2025...市場調査レポートについてご紹介

【英文タイトル】Non-Invasive Prenatal Testing Market Analysis by Gestation Period (0-12 weeks, 13-24 weeks, 25-36 weeks), by Pregnancy RiskLevel (High & Average Risk, Low Risk), By Region (U.S., UK, Germany, Japan, China, Brazil)And Segment Forecasts, 2014-2025

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

Table of Contents

Chapter 1 Research Methodology
1.1 Information Procurement
1.2 Data Analysis
Chapter 2 Executive Summary
Chapter 3 NIPT Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.1.1 Market driver analysis
3.1.1.1 Increasing average maternal age and rising incidence of chromosome syndromes
3.1.1.2 Presence of demand for early and Non-Invasive fetal testing procedure
3.1.1.3 Improvement in the reimbursement scenario
3.1.1.4 Presence of collaborations and licensing agreements
3.1.2 Market restraint analysis
3.1.2.1 Price erosion of the NIPT products
3.1.2.2 Ethical concerns with respect to reproductive genetics
3.2 Penetration & Growth Prospect Mapping, 2015
3.3 Non-Invasive prenatal testing – SWOT Analysis, By Factor (political & legal, economic and technological)
3.4 Industry Analysis – Porter’s
Chapter 4 NIPT Market: Gestation Duration Estimates & Trend Analysis
4.1 Non-Invasive Prenatal Testing: Gestation Duration Movement Analysis
4.2 0-12 weeks
4.2.1 Global NIPT 0-12 weeks, 2014 – 2025 (USD Million)
4.3 13-24 weeks
4.3.1 Global NIPT 13-24 weeks, 2014 – 2025 (USD Million)
4.4 25-36 weeks
4.4.1 Global NIPT 25-36 weeks, 2014 – 2025 (USD Million)
Chapter 5 NIPT Market: Risk Type Estimates & Trend Analysis
5.1 Non-Invasive Prenatal Testing: Risk Type Movement Analysis
5.2 High & Average Risk
5.2.1 Global high & average risk NIPT market, 2013 – 2025 (USD Million)
5.3 Low Risk
5.3.1 Global low risk NIPT market, 2013 – 2025 (USD Million)
Chapter 6 NIPT Market: Regional Estimates & Trend Analysis, by Gestation Period & Risk Type
6.1 Non-Invasive Prenatal Testing Share By Region, 2015 & 2025
6.2 North America
6.2.1 North America Non-Invasive prenatal testing, 2013 – 2025 (USD Million)
6.2.2 U.S.
6.2.2.1 U.S Non-Invasive prenatal testing culture market, 2013 – 2025 (USD Million)
6.2.3 Canada.
6.2.3.1 Canada Non-Invasive prenatal testing, 2013 – 2025 (USD Million)
6.3 Europe
6.3.1 Europe Non-Invasive prenatal testing, 2013 – 2025 (USD Million)
6.3.2 Germany.
6.3.2.1 Germany Non-Invasive prenatal testing, 2013 – 2025 (USD Million)
6.3.3 UK
6.3.3.1 UK Non-Invasive prenatal testing, 2013 – 2025 (USD Million)
6.4 Asia Pacific.
6.4.1 Asia Pacific Non-Invasive prenatal testing, 2013 – 2025 (USD Million)
6.4.2 China
6.4.2.1 China Non-Invasive prenatal testing, 2013 – 2025 (USD Million)
6.4.3 Japan
6.4.3.1 Japan Non-Invasive prenatal testing, 2013 – 2025 (USD Million)
6.5 Latin America.
6.5.1 Latin America Non-Invasive prenatal testing, 2013 – 2025 (USD Million)
6.5.2 Brazil
6.5.2.1 Brazil Non-Invasive prenatal testing, 2013 – 2025 (USD Million)
6.6 Middle East & Africa.
6.6.1 Middle East & Africa Non-Invasive prenatal testing, 2013 – 2025 (USD Million)
6.6.2 South Africa
6.6.2.1 South Africa Non-Invasive prenatal testing, 2013 – 2025 (USD Million)
Chapter 7 Competitive Landscape
7.1 Strategy framework
7.2 Market participation categorization
7.2.1 Natera Inc.
7.2.1.1 Company overview
7.2.1.2 Financial performance
7.2.1.3 Product benchmarking
7.2.1.4 Strategic initiatives
7.2.2 Illumina Inc. (Verinata Health, Inc.)
7.2.2.1 Company overview
7.2.2.2 Financial performance
7.2.2.3 Product benchmarking
7.2.2.4 Strategic initiatives
7.2.3 Sequenom Laboratories
7.2.3.1 Company overview
7.2.3.2 Financial performance
7.2.3.3 Product benchmarking
7.2.3.4 Strategic initiatives
7.2.4 Laboratory Corporation of America Holdings
7.2.4.1 Company overview
7.2.4.1 Financial Performance
7.2.4.2 Product benchmarking
7.2.4.3 Strategic initiatives
7.2.5 Quest Diagnostics
7.2.5.1 Company overview
7.2.5.2 Financial performance
7.2.5.3 Product benchmarking
7.2.5.4 Strategic initiatives
7.2.6 F. Hoffmann-La Roche Ltd (Ariosa Diagnostics)
7.2.6.1 Company overview
7.2.6.2 Financial performance
7.2.6.3 Product benchmarking
7.2.6.4 Strategic initiatives
7.2.7 BGI Diagnosis
7.2.7.1 Company overview
7.2.7.2 Financial performance
7.2.7.3 Product benchmarking
7.2.7.4 Strategic initiatives
7.2.8 LifeCodexx AG
7.2.8.1 Company overview
7.2.8.2 Financial performance
7.2.8.3 Product benchmarking
7.2.8.4 Strategic initiatives
7.2.9 Berry Genomics Co. Ltd.
7.2.9.1 Company overview
7.2.9.2 Financial performance
7.2.9.3 Product benchmarking
7.2.9.4 Strategic initiatives


【レポート販売概要】

■ タイトル:非侵襲的出生前検査の世界市場分析:妊娠期間別(0-12週、13-24週、25-36週)、妊娠リスクレベル別、(高リスク – 平均リスク、低リスク)、地域別(アメリカ、イギリス、ドイツ、日本、中国、ブラジル)、セグメント予測、2014-2025
■ 英文:Non-Invasive Prenatal Testing Market Analysis by Gestation Period (0-12 weeks, 13-24 weeks, 25-36 weeks), by Pregnancy RiskLevel (High & Average Risk, Low Risk), By Region (U.S., UK, Germany, Japan, China, Brazil)And Segment Forecasts, 2014-2025
■ 発行日:2016年12月2日
■ 調査会社:Grand View Research
■ 商品コード:GVIEW707592
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。